409 results match your criteria Journal of the Advanced Practitioner in Oncology JAdPrO [Journal]


Obstructive Dysphagia and Positional Dyspnea: Can You Identify the Cause?

Authors:
Kimberly Dotter

J Adv Pract Oncol 2018 May-Jun;9(4):441-444. Epub 2018 May 1.

Anderson Cancer Center.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347091PMC
May 2018
1 Read

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia.

J Adv Pract Oncol 2018 May-Jun;9(4):435-440. Epub 2018 May 1.

Indiana University Simon Cancer Center-IU Health, Indianapolis, Indiana.

Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations in isocitrate dehydrogenase (IDH) occur in 20% of AML diagnoses. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347084PMC
May 2018
1 Read

An Oncology NP-MD Partnership: Challenges and Rewards.

J Adv Pract Oncol 2018 May-Jun;9(4):430-433. Epub 2018 May 1.

Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, Washington, DC.

The State of Cancer Care in America report shines a spotlight on the significant increase of cancer survivors by 2026. One strategy to help care for the increased number of patients that require ongoing care is to hire more advanced practice providers. This article provides some keys to developing a positive, professional partnership with oncologists. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347089PMC

Clinical Management of Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy.

J Adv Pract Oncol 2018 May-Jun;9(4):422-428. Epub 2018 May 1.

The University of Texas MD Anderson Cancer Center, Houston, Texas.

A 48-year-old gentleman with metastatic melanoma currently receiving the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, ipilimumab (Yervoy), and the programmed cell death protein 1 (PD-1) inhibitor, nivolumab (Opdivo), returned for evaluation prior to receiving cycle 2. The patient presented with new onset dyspnea and a non-productive cough over the past week, with a temperature of 100.6°F at home on one occasion. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347088PMC
May 2018
2 Reads

Management of Advanced Bladder Cancer: An Update.

J Adv Pract Oncol 2018 May-Jun;9(4):410-416. Epub 2018 May 1.

Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Bladder cancer is the sixth most common cancer in the United States; therefore, the majority of clinicians working in the oncology setting will care for this patient population. Unfortunately, treatment plans, especially in the advanced setting, lack consistency. This, along with the advanced age and comorbidities of most bladder cancer patients, can provide challenges for clinicians when developing treatment plans. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347090PMC
May 2018
1 Read

Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment.

J Adv Pract Oncol 2018 May-Jun;9(4):392-405. Epub 2018 May 1.

University of Colorado, Aurora, Colorado.

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms varying in severity affecting one or more lines of hematopoiesis. Ineffective erythropoiesis results in dysregulation of iron metabolism. Most MDS patients have anemia, and some require regular red blood cell transfusions. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347085PMC
May 2018
1 Read

Feasibility of Outpatient High-Dose Methotrexate Infusions in Pediatric Patients With B-Lineage Acute Lymphoblastic Leukemia.

J Adv Pract Oncol 2018 May-Jun;9(4):381-386. Epub 2018 May 1.

Children's Mercy Hospital Kansas City, Kansas City, Missouri.

High-dose methotrexate (MTX) given in four hospitalizations during interim maintenance for high-risk pediatric B-lineage acute lymphocytic leukemia significantly improves survival but increases resource utilization. Children remain hospitalized for intravenous hydration and blood or urine monitoring until MTX clearance parameters are reached. Improved supportive care, extended infusion center hours, and pediatric home health expertise afford alternatives to prolonged hospital admissions, potentially offering quality, cost-effective approaches that positively impact the delivery of care. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347087PMC
May 2018
1 Read

Breast Cancer and Body Image Issues.

J Adv Pract Oncol 2018 May-Jun;9(4):375-376. Epub 2018 May 1.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347086PMC

JADPRO Live at APSHO 2017: Precision Thinking, Practical Knowledge.

J Adv Pract Oncol 2018 Apr 1;9(3):270-271. Epub 2018 Apr 1.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333560PMC

Diagnostic Snapshot: "I Have a Bad Cold".

J Adv Pract Oncol 2018 Mar 1;9(2):241-243. Epub 2018 Mar 1.

formerly of Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302999PMC

Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma.

J Adv Pract Oncol 2018 Mar 1;9(2):235-240. Epub 2018 Mar 1.

Levine Cancer Institute, Atrium Health, Rock Hill, South Carolina; and Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.

Olaratumab is a monoclonal antibody that recently received accelerated approval for the treatment of advanced soft-tissue sarcomas in combination with doxorubicin for a histologic subtype in which anthracycline-containing regimens is appropriate and disease is not amenable to curative surgery or radiotherapy. It inhibits platelet-derived growth factor receptor alpha, leading to the inhibition of tumor cell proliferation, angiogenesis, and metastasis. In a phase II clinical trial, olaratumab in combination with doxorubicin met its predefined primary endpoint of improving progression-free survival and secondary endpoint of overall survival compared to doxorubicin monotherapy in patients with advanced soft-tissue sarcoma. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303001PMC
March 2018
3 Reads

An Anecdotal Outpatient Approach to Caring for Patients With End-Stage Hematologic Malignancies.

Authors:
Mark Honor

J Adv Pract Oncol 2018 Mar 1;9(2):230-234. Epub 2018 Mar 1.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Historically, hospice has been a poor option for patients with end-stage hematologic malignancies, largely due to the need for regular transfusions to sustain life near the end, and to a lesser extent the treatment of curable emergent infections. In many cases, hospice is a viable and favorable option for patients with solid tumors who are out of treatment options yet have many months to live. For patients with hematologic malignancies with fewer than 6 months to live, although tens of transfusions may be required, they may have a relatively good quality of life when those transfusions are provided. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302997PMC
March 2018
6 Reads

Joining Forces: Establishing a Cardio-oncology Clinic.

J Adv Pract Oncol 2018 Mar 1;9(2):222-229. Epub 2018 Mar 1.

Yale University School of Nursing, New Haven, Connecticut.

Patients have been surviving cancer diagnoses at a steadily increasing rate over the past few decades. Despite the encouraging decline in cancer morbidity, the cardiovascular effect of some chemotherapy medications is concerning. Moreover, even though there is extensive knowledge of the pathophysiology and increased risk of cardiotoxicity, there is a lack of specific guidelines and adequate cardio-oncology programs focused on reducing cardiovascular risks or disease in patients undergoing cancer treatment. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303000PMC
March 2018
3 Reads

Paraneoplastic Encephalopathy in a Patient With Metastatic Lung Cancer: A Case Study.

Authors:
Scott M Rowley

J Adv Pract Oncol 2018 Mar 1;9(2):216-221. Epub 2018 Mar 1.

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

RS, a 36-year-old female, presented to the emergency department (ED) of a large academic medical center upon the advice of her primary care provider because of 3 weeks of progressive mental status changes, weakness, and decreased oral intake. According to her husband, RS was diagnosed with stage IIIA large cell lung cancer 8 months earlier and was treated with concurrent chemotherapy (carboplatin, pemetrexed, and bevacizumab) and radiation therapy that was completed 4 months prior to admission. No other specific information about her treatment or outside health records was available. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303004PMC
March 2018
19 Reads

Addressing the Symptom Management Gap in Patients With Cancer and Heart Failure Using the Interactive Voice Response System: A Pilot Study.

J Adv Pract Oncol 2018 Mar 1;9(2):201-214. Epub 2018 Mar 1.

Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, Boston, Massachusetts.

Patients with cancer and concurrent heart failure (HF) have severe symptoms that may adversely affect patients' quality of life in addition to limiting effective anticancer therapy. A system of frequent monitoring could alert clinicians, providing the opportunity for timely intervention before patients become severely ill and require hospitalization. The purpose of this pilot study was to evaluate if the MD Anderson Symptom Inventory-Heart Failure (MDASI-HF) instrument preprogrammed via the interactive voice response system (IVRS) can be used to collect symptom data that will generate symptom alerts to providers based on preset severity levels. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303007PMC
March 2018
1 Read

Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

J Adv Pract Oncol 2018 Mar 1;9(2):189-200. Epub 2018 Mar 1.

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania at the time of article submission, currently at Merck & Co., Inc, Kenilworth, New Jersey.

Inhibitors of the epidermal growth factor receptor (EGFR) are important treatment options for non-small cell lung cancer (NSCLC) patients with activating mutations. Erlotinib, gefitinib, afatinib, and osimertinib are approved for use in NSCLC patients, and several other agents are in clinical development. The objectives of this article are to review the pharmacokinetic and known drug interaction data for EGFR tyrosine kinase inhibitors (TKIs) available for use in NSCLC patients, as well as adverse events (AEs) commonly observed with EGFR-TKI treatment, and to discuss relevant management strategies. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302998PMC
March 2018
11 Reads

Acute Promyelocytic Leukemia: A Summary.

Authors:
Meaghan M Ryan

J Adv Pract Oncol 2018 Mar 1;9(2):178-187. Epub 2018 Mar 1.

Washington University School of Medicine, Saint Louis, Missouri.

Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia. The disease is characterized by a chromosomal abnormality involving translocation between chromosomes 15 and 17. Current therapy has advanced to include agents such as all- retinoic acid and arsenic trioxide, which have improved remission and survival rates. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303006PMC
March 2018
11 Reads

Cardiovascular and Cancer Risk: The Role of Cardio-oncology.

J Adv Pract Oncol 2018 Mar 1;9(2):160-176. Epub 2018 Mar 1.

Yale School of Nursing and Smilow Cancer Hospital, New Haven, Connecticut.

Cardio-oncology is a subspecialty of cardiology. It was created to address oncology data indicating that newly developed drugs for cancer treatment were having unanticipated cardiac side effects. Cardio-oncology designs primary and secondary risk strategies through surveillance as well as interventions to reduce cardiovascular risk (CVR), prevent cardiotoxicities, and manage the side effects that may occur. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303003PMC

Cardio-oncology: A Subspecialty in its Infancy.

J Adv Pract Oncol 2018 Mar 1;9(2):154-155. Epub 2018 Mar 1.

Dr. Coviello is associate professor at the Yale University School of Nursing and an adult nurse practitioner in cardio-oncology at the Smilow Cancer Hospital in New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303002PMC

Chemotherapy-Induced Nausea and Vomiting: Updates and Recommendations.

J Adv Pract Oncol 2018 Mar 1;9(2):150-152. Epub 2018 Mar 1.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303005PMC

Abstracts From JADPRO Live at APSHO 2017.

Authors:

J Adv Pract Oncol 2018 Jan-Feb;9(1):110-130. Epub 2018 Jan 1.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296423PMC
January 2018

Tender Nodules of the Foot.

Authors:
Carol Guarnieri

J Adv Pract Oncol 2018 Jan-Feb;9(1):103-105. Epub 2018 Jan 1.

HonorHealth Research Institute, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296419PMC
January 2018
1 Read

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

J Adv Pract Oncol 2018 Jan-Feb;9(1):94-101. Epub 2018 Jan 1.

Emory Winship Cancer Institute, Atlanta, Georgia; and Emory University Hospital, Atlanta, Georgia.

The treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the discovery of genetic driver mutations and associated targeted therapies. Anaplastic lymphoma kinase () mutations are present in about 5% of NSCLC cases, and treatment with the first-generation ALK inhibitor crizotinib has shown better progression-free survival (PFS) and response rate compared to traditional chemotherapy. However, eventually, -mutated NSCLC develops resistance to treatment with crizotinib, and second-generation ALK inhibitors such as ceritinib, brigatinib, and alectinib have been shown to be effective in the second-line setting after progression on crizotinib. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296421PMC
January 2018

Pharmaceutical Clinical Educators: A Resource for Advanced Practice Providers.

J Adv Pract Oncol 2018 Jan-Feb;9(1):86-89. Epub 2018 Jan 1.

Genentech, a Member of the Roche Group, Collegeville, Pennsylvania.

One of the main challenges within clinical practice today involves attaining the knowledge necessary to treat patients safely and effectively. The explosion of scientific breakthroughs within the health-care setting has created a new challenge for today's practitioners: staying informed. In turn, the pharmaceutical industry has been challenged with providing information that is accurate, meaningful, and compliant with US Food and Drug Administration guidelines. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296422PMC
January 2018

Precautions for Patients Taking Tamoxifen.

J Adv Pract Oncol 2018 Jan-Feb;9(1):78-83. Epub 2018 Jan 1.

Western Connecticut Health Network at The Smilow Family Breast Health Center, Norwalk Hospital, Norwalk, Connecticut.

Tamoxifen is a lifesaving treatment for millions of breast cancer patients worldwide. Yet taking tamoxifen may be challenging for some patients due to issues of compliance, drug interactions, and surgical considerations. Educating patients with a one-page teaching sheet, "Precautions for Patients Taking Tamoxifen," may improve tamoxifen's effectiveness and prevent complications. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296418PMC
January 2018

Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario.

J Adv Pract Oncol 2018 Jan-Feb;9(1):67-76. Epub 2018 Jan 1.

Duke Prostate Center, Durham, North Carolina.

Tom, a 75-year-old white male, was recently diagnosed with metastatic renal cell carcinoma (RCC; Tom's case is not an actual clinical case but has been developed by the authors as an exemplar). Two years prior, he had undergone a left partial (laparoscopic) nephrectomy for clear cell RCC. At that time, he had a stage 3 disease (the tumor extended into perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota's fascia [Cancer. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296420PMC
January 2018
2 Reads

The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera.

J Adv Pract Oncol 2018 Jan-Feb;9(1):56-66. Epub 2018 Jan 1.

The University of Arizona Cancer Center, Tucson, Arizona; and University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Mr. M, a 65-year-old male, presented to his primary care physician with progressive fatigue, difficulty sleeping, and daily headaches for the past 3 weeks. His headaches were not associated with visual disturbances, cognitive deficits, or nausea/vomiting, and he had no history of migraines. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296415PMC
January 2018
2 Reads

Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer.

Authors:
Emily Olson

J Adv Pract Oncol 2018 Jan-Feb;9(1):43-54. Epub 2018 Jan 1.

Mayo Clinic Cancer Center, Rochester, Minnesota.

About 17% of women with breast cancer have locally advanced or metastatic disease at the time of diagnosis, and 30% to 40% of women diagnosed with early-stage disease will eventually have recurrence. The majority of breast cancers express estrogen or progesterone receptors, and hormonal therapies (HTs) remain the treatment of choice for these cancers after the resection of primary tumors. In addition to their effectiveness, HTs often have fewer severe side effects compared with chemotherapies. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296414PMC
January 2018

Oncology Nurse Practitioner Web Education Resource(ONc-PoWER): An Evaluation of a Web-Enhanced Education Resource for Nurse Practitioners Who Are New to Cancer Care.

J Adv Pract Oncol 2018 Jan-Feb;9(1):27-37. Epub 2018 Jan 1.

University of Pittsburgh, School of Nursing, Pittsburgh, Pennsylvania.

The nurse practitioner (NP) new to an advanced role in a specialty practice may find the orientation period challenging while expanding his or her professional knowledge base. The Oncology Nurse Practitioner Web Education Resource (ONc-PoWER), a web-enhanced continuing education program, provides training for both the oncology NP (ONP) new to cancer care (i.e. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296413PMC
January 2018
6 Reads

It's Just the Flu...or Is It?

J Adv Pract Oncol 2018 Jan-Feb;9(1):18-19. Epub 2018 Jan 1.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296417PMC
January 2018

The SMARTIE Program: A Novel Initiative to Evaluate the Impact of AP Continuing Education on Clinical Practice.

J Adv Pract Oncol 2017 Nov-Dec;8(7):776-788. Epub 2017 Nov 1.

Harborside Medical Education, Lawrenceville, New Jersey.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188091PMC
November 2017

Oral Cancer Therapy: The Importance of Adherence.

Authors:

J Adv Pract Oncol 2017 Nov-Dec;8(7):773-774. Epub 2017 Nov 1.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188094PMC
November 2017

Hepatitis C Virus in the Hematology/Oncology Patient.

Authors:
Wendy H Vogel

J Adv Pract Oncol 2017 Nov-Dec;8(7):765-772. Epub 2017 Nov 1.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188090PMC
November 2017

Lenvatinib in the Treatment of Differentiated Thyroid Cancer and Advanced Renal Cell Carcinoma.

J Adv Pract Oncol 2017 Nov-Dec;8(7):757-764. Epub 2017 Nov 1.

Emory University Hospital, Atlanta, Georgia, and Baptist Health Lexington Lexington, Kentucky.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188100PMC
November 2017
1 Read

Immunotherapy Through the Years.

Authors:
Jessica Eno

J Adv Pract Oncol 2017 Nov-Dec;8(7):747-753. Epub 2017 Nov 1.

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188092PMC
November 2017

Li-Fraumeni Syndrome.

Authors:
Wendy H Vogel

J Adv Pract Oncol 2017 Nov-Dec;8(7):742-746. Epub 2017 Nov 1.

Wellmont Cancer Institute, Kingsport, Tennessee.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188099PMC
November 2017

Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non-Small Cell Lung Cancer.

J Adv Pract Oncol 2017 Nov-Dec;8(7):729-735. Epub 2017 Nov 1.

Seattle Cancer Care Alliance and Department of Medicine (Medical Oncology Division), University of Washington, Seattle, Washington; and Department of Medicine (Medical Oncology Division), University of Washington School of Medicine, Seattle, Washington.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188095PMC
November 2017
7 Reads

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q).

J Adv Pract Oncol 2017 Nov-Dec;8(7):721-728. Epub 2017 Nov 1.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

A male patient aged 67 years with a 2-year history of refractory anemia and myelodysplastic syndromes (MDS) with del(5q) started lenalidomide (Revlimid) treatment as a participant in the MDS-001 trial (List et al., 2005). At the time of the study, this patient had been transfusion-dependent since 2001, and at study entry he had received a total of 12 units of red blood cells (RBCs). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188096PMC
November 2017
1 Read

Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies.

J Adv Pract Oncol 2017 Nov-Dec;8(7):705-720. Epub 2017 Nov 1.

University of Memphis, School of Health Studies, Memphis, Tennessee.

Tumor lysis syndrome (TLS) is a potentially life-threatening emergency that can develop rapidly after the release of intracellular contents from lysed malignant cells. The advent of novel and targeted therapies that have improved tumor-killing efficacy has the potential to increase the risk of TLS when used as part of front-line therapy. A recent review of TLS risk in patients with hematologic malignancies treated with newer targeted agents highlighted the need to revisit TLS risk stratification and to describe the practical challenges of TLS prevention, treatment, and monitoring. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188097PMC
November 2017
15 Reads

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner.

J Adv Pract Oncol 2017 Nov-Dec;8(7):688-699. Epub 2017 Nov 1.

Greenville Health System Cancer Institute-Pharmacy, Greenville, South Carolina.

Biosimilar agents are biologic products that have been shown to be "highly similar" to an already approved reference biologic product. Their integration into clinical practice has the potential to significantly decrease costs for patients, health-care systems, and insurance companies. Through legislation, the US Food and Drug Administration (FDA) approved the Biologics Price Competition and Innovation (BCPI) Act in 2009. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188098PMC
November 2017
7 Reads

Psychosocial Distress as a Factor in Patients With Cancer Seeking Support: A Hermeneutic Study.

J Adv Pract Oncol 2017 Nov-Dec;8(7):680-686. Epub 2017 Nov 1.

Department of Nursing, Iran University of Medical Sciences, Tehran, Iran, and Department of Nursing, Modeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188101PMC
November 2017
6 Reads

Innovations in Cancer Therapies and Rising Costs.

J Adv Pract Oncol 2017 Nov-Dec;8(7):676-677. Epub 2017 Nov 1.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188093PMC
November 2017

The Oncology Care Model for Advanced Practitioners.

Authors:
Wendy H Vogel

J Adv Pract Oncol 2017 Sep-Oct;8(6):655-656. Epub 2017 Sep 1.

Wellmont Cancer Institute, Kingsport, Tennessee.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167084PMC
September 2017
5 Reads

Venetoclax: A Novel Treatment for Patients With del(17p) Chronic Lymphocytic Leukemia.

J Adv Pract Oncol 2017 Sep-Oct;8(6):647-652. Epub 2017 Sep 1.

University of Georgia College of Pharmacy and Augusta University Medical Center, Augusta, Georgia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167086PMC
September 2017

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen.

J Adv Pract Oncol 2017 Sep-Oct;8(6):639-645. Epub 2017 Sep 1.

Stamford, Connecticut.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167081PMC
September 2017

Role of the Advanced Practice Provider in Clinical Trials: Contributions to the Management of Patients Receiving Inotuzumab Ozogamicin.

J Adv Pract Oncol 2017 Sep-Oct;8(6):631-636. Epub 2017 Sep 1.

Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167080PMC
September 2017
7 Reads

Brentuximab Vedotin Infusion Reaction Management: A Case Study.

J Adv Pract Oncol 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 1.

Washington University School of Medicine, Siteman Cancer Center, St. Louis, Missouri.

We report a case of a grade 3 (Common Terminology Criteria for Adverse Events [CTCAE]) infusion reaction to brentuximab vedotin (Adcetris), in a patient with refractory Hodgkin lymphoma, at a large National Cancer Institute-designated cancer center in the Midwest (National Cancer Institute, 2010). Acute infusion reaction management and subsequent premedication strategies are outlined. Ms. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167082PMC
September 2017
2 Reads

Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner.

J Adv Pract Oncol 2017 Sep-Oct;8(6):609-620. Epub 2017 Sep 1.

Department of Pharmacy, Wake Forest Baptist Health Medical Center, Winston-Salem, North Carolina.

Mrs. P is a 30-year-old woman who presented to our bone marrow transplant program with myelodysplastic syndrome (MDS). She received a haploidentical allogeneic stem cell transplant with a conditioning regimen consisting of busulfan and cyclophosphamide. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167087PMC
September 2017
12 Reads

Cancer Pain Management: Opioid Analgesics, Part 2.

Authors:
Rita J Wickham

J Adv Pract Oncol 2017 Sep-Oct;8(6):588-607. Epub 2017 Sep 1.

Rush University College of Nursing (Adjunct Faculty), Chicago, Illinois.

Opioid analgesics are the cornerstone of moderate to severe cancer pain management, and do not have ceiling doses unless unmanageable adverse effects occur. Oral, short-acting pure μ agonists such as morphine are most frequently used, but other agents and administration formulations allow finding the right opioid and dose for most patients. In addition, clinicians must understand the metabolism, pharmacokinetics, and elimination of particular drugs to individualize opioid selection, select initial doses, and appropriately escalate doses to satisfactory pain relief or uncontrollable toxicity. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167083PMC
September 2017
14 Reads

Assessing the Plain Language Planner for Communication About Common Palliative Care Medications.

J Adv Pract Oncol 2017 Sep-Oct;8(6):575-580. Epub 2017 Sep 1.

Department of Communication, University of Memphis, Memphis, Tennessee.

Using plain language to communicate about oncology and palliative care medications and symptoms is recommended as a communication strategy to address patient/family health literacy demands. This study tested the Plain Language Planner©, a provider tool for communicating about medication and symptoms using plain language. Prior to and immediately following an oncology and palliative care nurse educational session, participants (n = 87) role-played about a symptom and medication. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167079PMC
September 2017
12 Reads